[1] |
RUBINSTEIN J H, TAYBI H. Broad thumbs and toes and facial abnormalities. A possible mental retardation syndrome[J]. Am J Dis Child, 1963, 105:588-608. DOI: 10.1001/archpedi.1963.02080040590010.
|
[2] |
VAN GILS J, MAGDINIER F, FERGELOT P,et al. Rubinstein-Taybi syndrome:a model of epigenetic disorder[J]. Genes (Basel), 2021, 12(7):968. DOI: 10.3390/genes12070968.
|
[3] |
MILANI D, MANZONI F M, PEZZANI L,et al. Rubinstein-Taybi syndrome:clinical features,genetic basis,diagnosis,and management[J]. Ital J Pediatr, 2015, 41:4. DOI: 10.1186/s13052-015-0110-1.
|
[4] |
PADFIELD C J, PARTINGTON M W, SIMPSON N E. The Rubinstein-Taybi syndrome[J]. Arch Dis Child, 1968, 43(227):94-101. DOI: 10.1136/adc.43.227.94.
|
[5] |
KALKHOVEN E, ROELFSEMA J H, TEUNISSEN H,et al. Loss of CBP acetyltransferase activity by PHD finger mutations in Rubinstein-Taybi syndrome[J]. Hum Mol Genet, 2003, 12(4):441-450. DOI: 10.1093/hmg/ddg039.
|
[6] |
SCHORRY E K, KEDDACHE M, LANPHEAR N,et al. Genotype-phenotype correlations in Rubinstein-Taybi syndrome[J]. Am J Med Genet A, 2008, 146A(19):2512-2519. DOI: 10.1002/ajmg.a.32424.
|
[7] |
BENTIVEGNA A, MILANI D, GERVASINI C,et al. Rubinstein-Taybi Syndrome:spectrum of CREBBP mutations in Italian patients[J]. BMC Med Genet, 2006, 7:77. DOI: 10.1186/1471-2350-7-77.
|
[8] |
WINCENT J, LUTHMAN A, VAN BELZEN M,et al. CREBBP and EP300 mutational spectrum and clinical presentations in a cohort of Swedish patients with Rubinstein-Taybi syndrome[J]. Mol Genet Genomic Med, 2015, 4(1):39-45. DOI: 10.1002/mgg3.177.
|
[9] |
NEGRI G, MILANI D, COLAPIETRO P,et al. Clinical and molecular characterization of Rubinstein-Taybi syndrome patients carrying distinct novel mutations of the EP300 gene[J]. Clin Genet, 2015, 87(2):148-154. DOI: 10.1111/cge.12348.
|
[10] |
BARTHOLDI D, ROELFSEMA J H, PAPADIA F,et al. Genetic heterogeneity in Rubinstein-Taybi syndrome:delineation of the phenotype of the first patients carrying mutations in EP300[J]. J Med Genet, 2007, 44(5):327-333. DOI: 10.1136/jmg.2006.046698.
|
[11] |
NEGRI G, MAGINI P, MILANI D,et al. From whole gene deletion to point mutations of EP300-positive Rubinstein-Taybi patients:new insights into the mutational spectrum and peculiar clinical hallmarks[J]. Hum Mutat, 2016, 37(2):175-183. DOI: 10.1002/humu.22922.
|
[12] |
SPENA S, GERVASINI C, MILANI D. Ultra-rare syndromes:the example of Rubinstein-Taybi syndrome[J]. J Pediatr Genet, 2015, 4(3):177-186. DOI: 10.1055/s-0035-1564571.
|
[13] |
RUSCONI D, NEGRI G, COLAPIETRO P,et al. Characterization of 14 novel deletions underlying Rubinstein-Taybi syndrome:an update of the CREBBP deletion repertoire[J]. Hum Genet, 2015, 134(6):613-626. DOI: 10.1007/s00439-015-1542-9.
|
[14] |
FERGELOT P, VAN BELZEN M, VAN GILS J,et al. Phenotype and genotype in 52 patients with Rubinstein-Taybi syndrome caused by EP300 mutations[J]. Am J Med Genet A, 2016, 170(12):3069-3082. DOI: 10.1002/ajmg.a.37940.
|
[15] |
RAMOS Y F, HESTAND M S, VERLAAN M,et al. Genome-wide assessment of differential roles for p300 and CBP in transcription regulation[J]. Nucleic Acids Res, 2010, 38(16):5396-5408. DOI: 10.1093/nar/gkq184.
|
[16] |
LIPINSKI M, DEL BLANCO B, BARCO A. CBP/p300 in brain development and plasticity:disentangling the KAT's cradle[J]. Curr Opin Neurobiol, 2019, 59:1-8. DOI: 10.1016/j.conb.2019.01.023.
|
[17] |
KALKHOVEN E. CBP and p300:hats for different occasions[J]. Biochem Pharmacol, 2004, 68(6):1145-1155. DOI: 10.1016/j.bcp.2004.03.045.
|
[18] |
PARK E, KIM Y, RYU H,et al. Epigenetic mechanisms of Rubinstein-Taybi syndrome[J]. Neuromolecular Med, 2014, 16(1):16-24. DOI: 10.1007/s12017-013-8285-3.
|
[19] |
BEDFORD D C, BRINDLE P K. Is histone acetylation the most important physiological function for CBP and p300? [J]. Aging, 2012, 4(4):247-255. DOI: 10.18632/aging.100453.
|
[20] |
|
[21] |
ALARI V, RUSSO S, TERRAGNI B,et al. iPSC-derived neurons of CREBBP- and EP300-mutated Rubinstein-Taybi syndrome patients show morphological alterations and hypoexcitability[J]. Stem Cell Res, 2018, 30:130-140. DOI: 10.1016/j.scr.2018.05.019.
|
[22] |
CALZARI L, BARCELLA M, ALARI V,et al. Transcriptome analysis of iPSC-derived neurons from Rubinstein-Taybi patients reveals deficits in neuronal differentiation[J]. Mol Neurobiol, 2020, 57(9):3685-3701. DOI: 10.1007/s12035-020-01983-6.
|
[23] |
ALARI V, SCALMANI P, AJMONE P F,et al. Histone deacetylase inhibitors ameliorate morphological defects and hypoexcitability of iPSC-neurons from Rubinstein-Taybi patients[J]. Int J Mol Sci, 2021, 22(11):5777. DOI: 10.3390/ijms22115777.
|
[24] |
DI FEDE E, OTTAVIANO E, GRAZIOLI P,et al. Insights into the role of the microbiota and of short-chain fatty acids in Rubinstein-Taybi syndrome[J]. Int J Mol Sci, 2021, 22(7):3621. DOI: 10.3390/ijms22073621.
|
[25] |
BABU A, KAMARAJ M, BASU M,et al. Chemical and genetic rescue of an ep300 knockdown model for Rubinstein Taybi Syndrome in zebrafish[J]. Biochim Biophys Acta Mol Basis Dis, 2018, 1864(4 Pt A):1203-1215. DOI: 10.1016/j.bbadis.2018.01.029.
|
[26] |
CROSS E, DUNCAN-FLAVELL P J, HOWARTH R J,et al. Screening of a large Rubinstein-Taybi cohort identified many novel variants and emphasizes the importance of the CREBBP histone acetyltransferase domain[J]. Am J Med Genet A, 2020, 182(11):2508-2520. DOI: 10.1002/ajmg.a.61813.
|
[27] |
PÉREZ-GRIJALBA V, GARCÍA-OGUIZA A, LÓPEZ M,et al. New insights into genetic variant spectrum and genotype-phenotype correlations of Rubinstein-Taybi syndrome in 39 CREBBP-positive patients[J]. Mol Genet Genomic Med, 2019, 7(11):e972. DOI: 10.1002/mgg3.972.
|
[28] |
SPENA S, MILANI D, RUSCONI D,et al. Insights into genotype-phenotype correlations from CREBBP point mutation screening in a cohort of 46 Rubinstein-Taybi syndrome patients[J]. Clin Genet, 2015, 88(5):431-440. DOI: 10.1111/cge.12537.
|